NOVACYT FULL YEAR 2017 RESULTS

Novacyt FY17 financial results Record revenue growth of 35% Significantly narrowed losses Positive outlook for 2018

Visit Page

NOVACYT SIGNS ASSAY DEVELOPMENT CONTRACT FOR DIAGNOSIS OF RESPIRATORY INFECTIONS WITH GENEPOC

Further validation of Novacyt’s expertise in developing assays for clinical applications Novacyt Signs Assay Development Contract for Diagnosis of Respiratory Infections with GenePOC Paris, France and Camberley, UK – 22 March 2018 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, today announces its molecular testing division, Primerdesign, has entered into

Visit Page

NOVACYT REVENUES FULL YEAR 2017

Novacyt revenues full year 2017 PR ENG Delivers record revenue growth of 35% China sales exceed expectations Successfully completed dual-listing on AIM

Visit Page